What we do Chandra Bhagat Pharma Limited markets pharmaceutical critical care and healthcare products including injections, tablets, and APIs mainly in India and for export. |
Founded in 2,003 |
Market share Established presence in major therapeutic categories like oncology, antibiotics, cardiovascular, and hormonal therapies with growing export markets. |
Problem solved Provides life-saving medicines addressing critical care needs in oncology, cardiology, antibiotics, and more, improving healthcare access domestically and internationally. |
Top clients or who we serve Pharmaceutical wholesalers, hospitals, and healthcare providers in India and international markets; operates in B2B and B2C segments. |
Key management Hemant Chandravadan Bhagat (Managing Director), Pranav Hemant Bhagat (Wholetime Director) |
Our journey and innovations Founded in 2003, transitioned from private to public in 2019, IPO in 2020 raised Rs 10.2 crores, expanded product portfolio and export presence. |
Where we operate Headquartered in Mumbai with a significant footprint across India and exports primarily to overseas markets. |
Top products or what we offer Pharmaceutical formulations including IV & IM injections, tablets, anti-cancer drugs, antibiotics, hormones, and APIs. |
Top brands - |
Raw materials needed Active Pharmaceutical Ingredients (APIs) and chemicals for formulations. |
Raw materials supplier Contract manufacturers approved by FDA and other third-party suppliers. |
Recurring vs cyclical contribution Revenue is largely recurring from pharmaceutical sales and exports. |
Our industry position Niche player with strong foothold in critical care and specialty pharmaceutical segments domestically and in exports. |
Financial highlights FY 2025 revenue Rs 86.7 crores; Net profit Rs 0.86 crores; focus on sustainable growth. |
Geographical revenue split Majority revenue from India with sizeable exports contributing significant foreign exchange earnings. |
Order book - |
Whats driving growth Growing demand for critical care medicines and expanded product portfolio fueling gradual revenue growth. |
Our future plans Plans to reinvest profits for expansion and increase market penetration in domestic and international markets. |
Our green promise Energy-saving initiatives like LED lighting adoption; commitment to conservation though limited capital expenditure currently. |
Our people and values Led by family promoters with experienced directors; emphasizes governance, ethics, and staff commitment. |
Key challenges ahead Managing growth sustainably amid competitive pharma markets and regulatory compliance. |
Interesting facts Converted from private to public in 2019; IPO raised Rs 10.2 crores; strong legacy through promoter family. |
Risks and strategy Operational and regulatory risks mitigated by robust internal controls, contract manufacturing, and compliance systems. |
